Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of aliskiren 300mg compared to irbesartan 300mg and ramipril 10 mg in the setting of a missed dose for patients with essential hypertension.

Conditions: Essential Hypertension

Summary: the purpose of this study is to investigate the efficacy (blood pressure lowering effect) and safety of aliskiren given to hypertensive patients after a missed dose.


Eligibility criteria:
inclusion criteria: * outpatients 18 years of age and older. * patients must meet following blood pressure criteria: at visit 2 : office mean sitting diastolic blood pressure ≥ 90 mmhg and \< 110 mmhg at visit 3 : office mean sitting diastolic blood pressure ≥ 95 mmhg and \< 110 mmhg before application of ambulatory blood pressure measurement device at visit 3 : 24-hr mean ambulatory diastolic blood pressure ≥ 85 mmhg * patient must have an absolute difference of ≤ 10 mmhg in their office mean sitting diastolic blood pressure between visit 2 and 3. * male or female patients are eligible. female patients must be either post-menopausal for at least one year, surgically sterile or using effective contraceptive methods such as oral contraceptives, barrier method with spermicide or an intrauterine device. reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation. * patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent). exclusion criteria: * severe hypertension \[office mean sitting diastolic blood pressure ≥ 110 mmhg and/or office mean sitting systolic blood pressure (mssbp) ≥ 180 mmhg\]. * current diagnosis of heart failure (nyha class ii-iv). * history of myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (pci) during the 12 months prior to visit 1. * known or suspected contraindications to the study medications, including history of allergy to ace-inhibitors or arbs. * upper arm circumference \> 42 cm. * third shift or night workers. other protocol-defined inclusion/exclusion criteria may apply

Keywords: hypertension, ambulatory blood pressure, missed dose, aliskiren
treating comorbid pain and depression in hiv+ individuals

Conditions: HIV; Depression; Pain

Summary: this study is designed to look at two different programs that may help people who are hiv+ and have pain and depression. the investigators are trying to understand how to help people learn to live better lives even with these chronic illnesses.

the primary aim of this rct is to evaluate the hivpass intervention. hiv+ participants (n=236) with chronic pain and depression will be recruited at primary care hiv clinics through posted advertisements in the waiting rooms of the pcp offices and by physician referral. after an initial phone study screen, research staff will meet with interested individuals in their pcp offices for informed consent, baseline interview and randomization into one of two study groups (health education or hivpass counseling). seven intervention sessions (he or hivpass) will occur during the first 3 months of study participation. for all participants, the first session is a collaborative in-person joint session with the participant, his/her pcp and the study bhs. session 2 is conducted immediately after this collaborative session, and is also in-person. sessions 3-7 are conducted by phone. follow-up assessment interviews will be at months 1, 2, 3 (post-intervention), 4, 6, 9 and 12.

Eligibility criteria:
inclusion criteria: * chronic pain (pain duration for at least six months with a mean score of greater than 3.5 on the bpi pain interference scale) * pain severity \> or equal to 4 on a numeric rating scale indicating "average pain in the last week" * at least one trial of pcp-recommended medication (i.e. acetaminophen, nsaids, muscle relaxants) judged through interviews with patients and pcps * quick inventory of depression symptoms (qids) score of ≥ 9 (depression severity) * stable dose of an antidepressant, if using, for the previous 1 months * age \> or equal to 18 * hiv+ * planning to live in the area for the next 6 months * access to a telephone that is typically working. exclusion criteria: * in psychotherapy or a multidisciplinary pain management program * planned surgery in the next 6 months * pain thought due to cancer * current mania * past year chronic psychotic condition * excessive substance use (use of cocaine, heroin, or non-prescribe opioids 15 days per month or more; binge alcohol use 4 days per month or more) * suicidality requiring immediate attention * pregnancy or planned pregnancy in the next 6 months
a study to investigate the anti-plaque effect of an0128 toothpaste

Conditions: Dental Plaque

Summary: the objective of this study was to evaluate the anti-plaque efficacy of the anacor prototype dentrifice as compared to commercial control products following a single use of the dentrifice.

the widespread successful use of triclosan as an anti-inflammatory and anti-bacterial agent is well documented. the standard dentrifice has demonstrated a robust anti-plaque and anti-inflammatory effect providing multiple benefits. there is a clear value to identify additional agents with the same dual action with a comparable or an enhanced level of efficacy. this study examined the anti-plaque efficacy following a single use of the prototype dentifrice.

Eligibility criteria:
inclusion criteria: * must be between ages 18 to 65 years inclusive * have a minimum of 16 natural uncrowned teeth (excluding 3rd molars) present * must give written informed consent * be in good general health * must discontinue oral hygiene for 24-hours after initial appointment * no known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study exclusion criteria: * medical condition which requires pre-medication prior to dental visits/procedures * advanced periodontal disease * 5 or more decayed, untreated dental sites * diseases of the soft or hard oral tissues * orthodontic appliances * abnormal salivary function * use of drugs that can affect salivary flow * use of antibiotics one (1) month prior to or during this study * use of any over the counter medications other than analgesics (i.e. aspirin, ibuprofen, acetaminophen, naproxen), unless approved by the study medical staff * pregnant or breastfeeding * participation in another clinical study in the month preceding this study * allergic to common dentifrice ingredients * immune compromised individuals (hiv, aids, immuno suppressive drug therapy) * history of allergic reaction to any anti-inflammatory agents

Keywords: dental plaque
hfcs, apple juice, excess free fructose & asthma-the fhs-os

Conditions: Asthma

Summary: perform an exploratory analysis of association between consumption of high excess free fructose (eff) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice) and chronic bronchitis (cb)/history of cb, and asthma/ history of asthma.


Eligibility criteria:
inclusion criteria: * participants in the fhs offspring who answered questions in the ffq about soft drinks, fruit drinks and fruit juice consumption; participants with non-missing data for the exposures and potentially confounding variables of interest. exclusion criteria: * extreme energy intake on food frequency questionnaire (defined as ≤600 kcal/day or ≥4800 kcal/day)
a multiple dose crossover pharmacokinetics study to evaluate the effects of food on the absorption of oral ganciclovir

Conditions: Cytomegalovirus Infections; HIV Infections

Summary: this study is designed to determine the influence of food on the absorption and relative bioavailability of oral ganciclovir by comparing the absorption of oral ganciclovir in a fed and fasting state at steady state plasma levels.


Eligibility criteria:
inclusion criteria patients must have the following: * confirmation of hiv infection by hiv antibody testing, p24 antigen, or culture of hiv. * documented confirmation of present or past cmv infection. * must understand the nature of the study, agree to tests required in the protocol, and must understand and sign an informed consent form approved by the appropriate institutional review board and by syntex. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * uncontrolled diarrhea or clinically significant gastrointestinal symptoms including persistent nausea or abdominal pain. concurrent medication: excluded: * antimetabolites. interferons. other nucleoside analogs. zidovudine (azt). any investigational drug. patients with the following are excluded: * any concomitant conditions listed in exclusion co-existing conditions. * karnofsky score \< 70. * hypersensitivity to acyclovir. * displaying signs of dementia or decreased mentation which would interfere with the ability of the subject to follow protocol schedule. prior medication: excluded: * anti-cytomegalovirus therapy including ganciclovir therapy for treatment of cmv disease. * excluded within 4 days of study entry: * antimetabolites. * interferons. * other nucleoside analogs. * zidovudine (azt).

Keywords: aids-related opportunistic infections ganciclovir cytomegalovirus infections acquired immunodeficiency syndrome biological availability
the care (collaborative adolescent running experience) project

Conditions: Depression; Anxiety; Major Depressive Disorder; Bipolar Disorder

Summary: this study is being completed to see if participants activity levels may have an impact as a treatment for depression, or depressive symptoms. eligible participants will be enrolled and have an 8-week running intervention three times each week. the study hypothesizes that adolescents with psychiatric disorders that are experiencing depressive symptoms will participate in a supported running intervention.


Eligibility criteria:
inclusion criteria: * psychiatric disorders that are experiencing depressive symptoms (defined by the protocol) * must have a smart phone * parents/guardians will be advised to discuss their child's participation in the intervention with the participant's primary care physician exclusion criteria: * adolescents with unstable cardiac, pulmonary, endocrine or renal disorders * adolescents with previous injuries or other conditions that may impact the safety of a running intervention

Keywords: running adolescents
biweekly docetaxel in patients with metastatic breast cancer.

Conditions: Metastatic Breast Cancer

Summary: there is clinical benefit of docetaxel administered to patients who have progressed to 3 or more lines of chemotherapy including prior exposure to paclitaxel or docetaxel; using docetaxel in metastatic stage breast cancer previously exposed to taxanes equal therapeutic responses are obtained that it never received taxanes.

methodology: prospective non-randomized phase iia. the selected patients with metastatic breast cancer heavily pretreated including those previously treated with taxanes, receive docetaxel administered at a dose of 45mg/m2 body surface every 2 weeks to assess the activity of this drug. variables: age. menopausal status. hormone receptor status. overexpression of her2 neu. location of metastatic sites. performance status (ps) 0-3. comorbidities. case management in the variables (patient subgroups ) the patients with her 2 neu overexpression of anti -her2 therapy will further chemotherapy with docetaxel. the patients presenting with brain metastases may receive radiation therapy to the brain and then at the end of radiotherapy, start docetaxel. patients whose tumors express estrogen receptors and progesterone positive receive treatment with docetaxel: where there is visceral crisis and it is shown that they have already progressed to more than 2 lines of previously administered hormone treatment. in no event cytotoxic chemotherapy with concurrent docetaxel was administered to an anti-estrogen drug. and they can continue only when hormone therapy has achieved complete response measurable lesions with docetaxel and opt for a non-cytotoxic anti-estrogen therapy and when it came to presenting unacceptable toxicity with docetaxel. evaluations: clinical assessment that will include physical examination and review of laboratory studies were carried out every 2 weeks before authorizing the housing management of a next cycle. the objective assessment of tumor response was carried out by imaging studies (ct) by recist criteria after administration of the 4 criteria of cycles, a cycle is administered every 2 weeks with docetaxel at a dose of 45mg/m2. response criteria 1. response tumor shrinkage by royalty over 30%. 2. greater than 1 cm in the size of tumor lesions decrease. 3. disease-free survival 4. progression-free survival. 5. stable disease 6. improved quality of life that is decreased bone pain, improvement of dyspnea.

Eligibility criteria:
inclusion criteria: women over 21 years of age diagnosed with breast cancer in clinical stage iv, who had received 3 or more lines of cytotoxic chemotherapy, which may have included paclitaxel or docetaxel, which have measurable or evaluable tumor activity in any distant organ and who are fully conscious and well oriented to permit informed consent. exclusion criteria: male patients with metastatic breast cancer. patients with grade 3 neuropathy by prior exposure to taxanes. patients under 21 and over 85 years of age. metastasis of one site in the central nervous system.

Keywords: metastatic breast cancer taxanes heavily pretreated
time effect on the predictability of different grafting for gingival recession rt 1

Conditions: Gingival Recession Types One(RT1)

Summary: the primary objective of this study was to evaluate time effect on the clinical predictability of collagen matrix xenograft (cmx) with melatonin gel versus connective tissue graft (ctg) and determine whether it is proposed to be an alternative in multiple adjacent gingival recession (magr) in recession type one (rt1)

this study was conducted to evaluate time effect on the clinical predictability of collagen matrix xenograft (cmx) with melatonin gel versus connective tissue graft (ctg) and determine whether it is proposed to be an alternative in multiple adjacent gingival recession

Eligibility criteria:
inclusion criteria: * presence of rt1 grs of the maxillary or mandibular arch in the esthetic zone with a gr depth ≥2 mm, * patients \>18 years old, * full mouth plaque index score \<20% * systemically and periodontally healthy patients. exclusion criteria: * smokers * patients with periodontitis stage iii and iv were previous surgical treatment of gr, * pregnant or breastfeeding women; p * patients with para-functional habits or any source of occlusal trauma.
application of hyperspectral imaging in the diagnosis of glomerular diseases

Conditions: Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Diabetic Nephropathies; Nephrosis, Lipoid; Hyperspectral Imaging

Summary: morning urine samples of patients with iga nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and minimal degenerative nephropathy confirmed by renal needle biopsy in our hospital from november 2020 to january 2022 were collected. by scanning the morning urine samples of corresponding patients with microhyperspectral imager, machine learning and deep learning were used to classify microhyperspectral images, and the classification accuracy was greater than 85%. thus, hyperspectral imaging technology could be used as a non-invasive diagnostic means to assist the diagnosis of glomerular diseases.


Eligibility criteria:
inclusion criteria: * over 18 years old; * patients with iga nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, minimal change nephropathy confirmed by renal biopsy; * had not received hormone and/or immunosuppressive therapy before renal biopsy; * complete clinical data, all signed the "admission certificate of qianfoshan hospital of shandong province", and agreed to use relevant medical information, biological specimen examination and examination results for scientific research. exclusion criteria: * there are factors causing secondary membranous nephropathy, such as immune diseases (systemic lupus erythematosus), tumors/infections (viral hepatitis), drugs or poisons, etc.; * severe infection: fever, cough and expectoration, sore throat, abdominal pain, diarrhea, carbuncle and furuncle and other clinical manifestations of skin and soft tissue infection, blood routine white blood cell count beyond the normal range (10×109/l); * severe cardiovascular disease: including chronic heart failure grade 3 or above and various arrhythmias; * infectious diseases: active hepatitis, aids, syphilis, etc. ; * tumor evidence: it has been found that there is a certain tumor or clinical manifestations, tumor markers, etc., suggesting the possibility of tumor.
myocardial perfusion imaging by 15o-h2o pet/ct

Conditions: Ischemic Heart Disease

Summary: the trial will include 5000 patients with evident or suspected ischemic heart disease refered to department of nuclear medicine \& pet centre, aarhus university hospital, for perfusion imaging by 15o-h2o pet/ct scan of the heart during rest and stress. the patients will undergo the clinical scan as normal. data from the scans will be used to determine reference values of the examination. follow up will be done for up to 10 years in regards to major cardiovascular events in order to determine the prognostic value of the scan.


Eligibility criteria:
inclusion criteria: * known or suspected ischemic heart disease referred for a clinical h2o-pet at department of nuclear medicine and pet centre, aarhus university hospital exclusion criteria: * claustrophobia, severe asthma, younger than 18 years

Keywords: myocardial perfusion imaging positron-emission tomography coronary artery disease coronary flow reserve myocardial blood flow prognosis reference value
efficacy of low-intensity shockwave therapy in treating radiation cystitis

Conditions: Radiation Cystitis

Summary: radiation-induced cystitis is a condition commonly seen in patients who have undergone radiation therapy, especially those treated in the pelvic region. symptoms typically manifest after radiation exposure and may include dysuria (painful urination), increased urinary frequency during both day and night, and hematuria (blood in the urine), which can range from mild to severe. currently, treatment is symptomatic, as there is no definitive cure for radiation cystitis. management includes medications to alleviate symptoms, cystoscopic interventions to control bleeding, intravesical instillations, and in severe cases, surgical procedures to divert the urinary tract. recently, low-intensity extracorporeal shock wave therapy (li-eswt) has been used to treat various urological conditions, including chronic prostatitis, chronic cystitis, overactive bladder, erectile dysfunction, and as an adjunct to enhance drug delivery into the bladder. this modality has shown potential to reduce inflammation, promote angiogenesis (formation of new blood vessels), regenerate tissues, and restore neural function. for patients with radiation cystitis, particularly those with prostate cancer who have received pelvic radiation, shock wave therapy is being explored for its ability to alleviate bladder pain and inflammation. this approach is similar to its use in non-bacterial cystitis and overactive bladder conditions. studies have identified elevated levels of specific proteins in the urine of patients with radiation-induced cystitis, including markers of fibrosis, angiogenesis, and inflammation, which differ from those found in non-irradiated individuals. the anticipated benefit of this study is to provide data on clinical symptoms and treatment safety, potentially offering a novel therapeutic strategy for managing radiation-induced cystitis.


Eligibility criteria:
inclusion criteria: * criteria for diagnosis of radiation-induced cystitis and a history of pelvic radiation therapy administered more than 6 months prior. * aged 18 years or older. * willing to participate in the research study by providing written informed consent. exclusion criteria: * active urinary tract infection within the past 6 months. * active and uncontrolled gross hematuria. * patients currently have a urinary diversion or abdominal ostomy. * patients with anuria due to chronic kidney failure. * uncontrolled coagulopathy. * refuse participation, withdraw from the study, or experience severe adverse effects.

Keywords: radiation cystitis li-eswt
cholgate - the effect of alerting versus on demand computer based decision support on treatment of dyslipidaemia by general practitioners

Conditions: Decision Support Systems, Clinical

Summary: indirect evidence show alerting physicians with clinical decision support systems (cdss) seem to change behaviour more than requiring users to actively initiate the system. however, randomized trials comparing these methods in a clinical setting are lacking. in this study we compare the effect of alerting physicians with a cdss or actively requiring initiation of cdss on the adherence of dutch general practitioners to the cholesterol guideline of the dutch college of general practitioners.

indirect evidence show alerting physicians with clinical decision support systems (cdss) seem to change behaviour more than requiring users to actively initiate the system. however, randomized trials comparing these methods in a clinical setting are lacking. in this study we compare the effect of alerting physicians with a cdss or actively requiring initiation of cdss on the adherence of dutch general practitioners to the cholesterol guideline of the dutch college of general practitioners, using a clinical decsion support system called cholgate. this system has the functionality to provide both alerting and on-demand decision support. users are free to negate the advise provided by the decision support system. the trial will have a cluster randomized structure.

Eligibility criteria:
inclusion criteria: * all general practices using only elias electronic patient records (isoft b.v) * all patients meeting the screening and treatment criteria of the dutch college of general practitioners cholesterol guideline exclusion criteria: * practices that used paper based records